MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

United Therapeutics Corp

Fechado

SetorSaúde

312.14 1.91

Visão Geral

Variação de preço das ações

24h

Atual

Mín

299.98

Máximo

312.82

Indicadores-chave

By Trading Economics

Rendimento

-7.8M

301M

Vendas

-13M

736M

P/E

Médio do Setor

12.506

63.778

EPS

6.19

Margem de lucro

40.943

Funcionários

1,305

EBITDA

6.3M

424M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+23.18% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.7B

14B

Abertura anterior

310.23

Fecho anterior

312.14

Sentimento de Notícias

By Acuity

7%

93%

3 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

United Therapeutics Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2024, 15:14 UTC

Grandes Movimentos do Mercado

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 de jan. de 2025, 10:30 UTC

Principais Notícias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparação entre Pares

Variação de preço

United Therapeutics Corp Previsão

Preço-alvo

By TipRanks

23.18% parte superior

Previsão para 12 meses

Média 384.64 USD  23.18%

Máximo 460 USD

Mínimo 293 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para United Therapeutics Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

8

Comprar

3

Manter

1

Vender

Pontuação Técnica

By Trading Central

307.64 / 312.61Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

3 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.